JP2025515307A - 炎症を治療するためのトランスクリプトーム解析 - Google Patents

炎症を治療するためのトランスクリプトーム解析 Download PDF

Info

Publication number
JP2025515307A
JP2025515307A JP2024562852A JP2024562852A JP2025515307A JP 2025515307 A JP2025515307 A JP 2025515307A JP 2024562852 A JP2024562852 A JP 2024562852A JP 2024562852 A JP2024562852 A JP 2024562852A JP 2025515307 A JP2025515307 A JP 2025515307A
Authority
JP
Japan
Prior art keywords
dupilumab
genes
treatment
gene expression
nes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024562852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515307A5 (https=
Inventor
キアット リム、ウェイ
ゲイバート、ケイトリン
ハレル、シヴァン
デビッドソン ハミルトン、ジェニファー
ハモン、サラ
エフ． ワイパーマン、マシュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2025515307A publication Critical patent/JP2025515307A/ja
Publication of JP2025515307A5 publication Critical patent/JP2025515307A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2539/00—Reactions characterised by analysis of gene expression or genome comparison
    • C12Q2539/10—The purpose being sequence identification by analysis of gene expression or genome comparison characterised by
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024562852A 2022-04-26 2023-04-25 炎症を治療するためのトランスクリプトーム解析 Pending JP2025515307A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263334837P 2022-04-26 2022-04-26
US63/334,837 2022-04-26
PCT/US2023/066197 WO2023212569A1 (en) 2022-04-26 2023-04-25 Transcriptome analysis for treating inflammation

Publications (2)

Publication Number Publication Date
JP2025515307A true JP2025515307A (ja) 2025-05-14
JP2025515307A5 JP2025515307A5 (https=) 2026-04-15

Family

ID=86469406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024562852A Pending JP2025515307A (ja) 2022-04-26 2023-04-25 炎症を治療するためのトランスクリプトーム解析

Country Status (8)

Country Link
US (1) US20230340601A1 (https=)
EP (1) EP4514995A1 (https=)
JP (1) JP2025515307A (https=)
CN (1) CN119137282A (https=)
AU (1) AU2023259352A1 (https=)
CA (1) CA3246860A1 (https=)
MX (1) MX2024013120A (https=)
WO (1) WO2023212569A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117949666B (zh) * 2024-01-12 2025-07-15 首都医科大学附属北京同仁医院 一种预测或评估抗IL-4Rα单抗在治疗鼻黏膜2型炎症相关鼻病疗效的标志物、方法和应用
WO2025244092A1 (ja) * 2024-05-23 2025-11-27 国立研究開発法人理化学研究所 アトピー性皮膚炎患者へのデュピルマブの投与の有効性を予測する方法及びキット
WO2025244094A1 (ja) * 2024-05-23 2025-11-27 国立研究開発法人理化学研究所 アトピー性皮膚炎患者へのデュピルマブの投与の有効性を予測する方法及びキット
CN119932179B (zh) * 2025-04-08 2025-06-27 杭州易文赛生物技术有限公司 用于评价间充质干细胞治疗炎症性肠炎效果的标志物组合物及其应用
CN120510912A (zh) * 2025-05-20 2025-08-19 北京大学人民医院 用于溃疡性结肠炎预测计算机装置及计算机可读存储介质
CN121109581B (zh) * 2025-11-17 2026-03-06 杭州易文赛生物技术有限公司 用于评价间充质干细胞治疗特应性皮炎效果的标志物组合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR098155A1 (es) * 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos
WO2019217478A1 (en) * 2018-05-09 2019-11-14 Dermtech, Inc. Novel gene classifiers and uses thereof in autoimmune diseases
EP4153300A1 (en) * 2020-05-22 2023-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor

Also Published As

Publication number Publication date
US20230340601A1 (en) 2023-10-26
WO2023212569A1 (en) 2023-11-02
EP4514995A1 (en) 2025-03-05
MX2024013120A (es) 2024-12-06
AU2023259352A1 (en) 2024-10-10
CN119137282A (zh) 2024-12-13
CA3246860A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
US12105089B2 (en) Cell atlas of the healthy and ulcerative colitis human colon
US12534763B2 (en) Systems and methods of diagnosing idiopathic pulmonary fibrosis
US20230340601A1 (en) Transcriptome Analysis For Treating Inflammation
US20210047694A1 (en) Methods for predicting outcomes and treating colorectal cancer using a cell atlas
US10166210B2 (en) Methods of subtyping CRC and their association with treatment of colon cancer patients with oxaliplatin
US20200347456A1 (en) Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
EP3458611B1 (en) Methods for subtyping of lung squamous cell carcinoma
US20240282449A1 (en) Methods and systems for machine learning analysis of inflammatory skin diseases
US20220399116A1 (en) Systems and methods for assessing a bacterial or viral status of a sample
US20210139987A1 (en) Methods, computer-readable media, and systems for assessing samples and wounds, predicting whether a wound will heal, and monitoring effectiveness of a treatment
US20150315643A1 (en) Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
US20230220470A1 (en) Methods and systems for analyzing targetable pathologic processes in covid-19 via gene expression analysis
US20190367964A1 (en) Dissociation of human tumor to single cell suspension followed by biological analysis
US20250011886A1 (en) Systems and Methods for Targeting COVID-19 Therapies
US20250391505A1 (en) Methods and Systems for Machine Learning Analysis of Lupus Nephritis
US11815509B2 (en) Cell line and uses thereof
US20240150453A1 (en) Methods of predicting response to anti-tnf blockade in inflammatory bowel disease
US20210071250A1 (en) Diagnostic and prognostic liquid biopsy biomarkers for asthma
EP4676593A1 (en) Diagnosing and treating atopic dermatitis, psoriasis, and/or mycosis fungoides
US20240229166A9 (en) Methods of stratifying and treating coronavirus infection
Pushparaj Translational interest of immune profiling
US20260117297A1 (en) Longitudinal Gene Expression Analysis of Inflammatory Skin Diseases
Chen Active Acquisition Methods for Single Cell Genomics
Allen Genetic Basis for Elevated Rheumatic Heart Disease Susceptibility in Samoa
HK40006869A (en) Methods for subtyping of lung squamous cell carcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260313